GLUT-1 expression is helpful to distinguish myxofibrosarcoma from nodular fasciitis

Histol Histopathol. 2023 Jan;38(1):47-51. doi: 10.14670/HH-18-490. Epub 2022 Jul 6.

Abstract

Myxofibrosarcoma (MFS) is a fibroblastic/myofibroblastic neoplasm with a variably myxoid stroma. Histologically, MFS shows a wide spectrum of cellularity, pleomorphism and proliferative activity. Because of its variable morphology and lack of discriminatory markers, MFS can be difficult to distinguish from some benign soft-tissue tumors, especially nodular fasciitis (NF). Glucose transporter 1 (GLUT-1) is expressed in a variety of malignant mesenchymal tumors. In the current study, we evaluated GLUT-1 expression to determine its value in distinguishing MFS from NF. Tissue specimens from 14 MFS cases and 16 NF cases were sectioned and stained for GLUT-1 using immunohistochemistry. The percentage of GLUT-1-positive cells was scored as follows: 0 (no staining), 1+ (1-19%), 2+ (20-50%) and 3+ (>50%). Samples with a score of 1+ were defined as GLUT1-expressing samples. GLUT-1 expression was seen in all 14 MFS cases, whereas only 6 NF cases (37.5%) were positive for GLUT-1 and were scored 1+. Notably, 2-3+ GLUT-1 expression was found in 86% of MFS cases and 0% of NF cases. Our results indicate that GLUT-1 is a highly sensitive immunohistochemical marker for MFS and may be useful for the differential diagnosis of MFS and NF.

MeSH terms

  • Adult
  • Biomarkers, Tumor / metabolism
  • Diagnosis, Differential
  • Fasciitis* / diagnosis
  • Fasciitis* / pathology
  • Fibrosarcoma* / diagnosis
  • Fibrosarcoma* / pathology
  • Humans
  • Immunohistochemistry
  • Sarcoma* / pathology
  • Soft Tissue Neoplasms* / pathology

Substances

  • Biomarkers, Tumor